Evidence map›Paper›PMID 42449929›Full record

ArticleInternational journal of molecular sciences2026

Transcriptional Profiling Shows Dampening of Interferon Gene Signatures by NAD

Veronica Suaste, Rebecca Presterud, Anna B Wennerström, He-Ling Wang, Jianying Zhang, Solveig Osnes Lund, Helle Graneng Holmen, Torben Lüders, Alexander Rowe, Rolf Kristian Berge and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Veronica SuasteDepartment of Biosciences, University of Oslo, 0317 Oslo, Norway.ORCID 0009-0009-4446-9445
Rebecca PresterudInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.ORCID 0009-0009-9923-0095
Anna B WennerströmDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0001-8143-9944
He-Ling WangDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0002-8920-1487
Jianying ZhangDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0001-8161-7536
Solveig Osnes LundDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0002-0254-2474
Helle Graneng HolmenInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.
Torben LüdersDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0001-5176-7808
Alexander RoweNorwegian National Unit for Newborn Screening, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, 0373 Oslo, Norway.
Rolf Kristian BergeDepartment of Chemistry, University of Bergen, 5020 Bergen, Norway.
Lisa LirussiDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0002-2111-5152
Yohan LefolDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.
Lene AlsøeDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0002-8711-8479
Evandro Fei FangDepartment of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway.ORCID 0000-0003-0355-7202
Asbjørg Stray-PedersenNorwegian National Unit for Newborn Screening, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, 0373 Oslo, Norway.ORCID 0000-0002-9168-0878
Hilde Loge NilsenDepartment of Microbiology, Oslo University Hospital, 0424 Oslo, Norway.ORCID 0000-0003-2115-2663

Funding

Euripean Union - Marie Sklodowska-Curie Action Nº 945371KLINSK BEHANDLINGSFORSKNING 26034The Research Council of Norway 332713Wellcome Trust
6 · The paper itself

Abstract

Ataxia-Telangiectasia (A-T) is a multisystem disorder caused by loss of A-T mutated (ATM) protein activity, characterized clinically by immunodeficiency and cerebellar ataxia. ATM is a master regulator of DNA damage responses and loss of ATM function is accompanied by persistent activation of PARP1 leading to depletion of intracellular NAD

Indexed as

Ataxia TelangiectasiaGene Expression ProfilingInterferonsNADTranscriptomeHumansLeukocytes, MononuclearNiacinamidePyridinium CompoundsSignal TransductionInterferonsNADNiacinamidenicotinamide-beta-ribosidePyridinium CompoundsAtaxia-Telangiectasiainterferon gene signatureNAD+nicotinamide ribosidetranscription profiling

Identifiers

PMID42449929
PMCPMC13362275

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.